The 2025 multiple sclerosis (MS) conferences served as the primary venues for unveiling breakthroughs in remyelination, Bruton’s tyrosine kinase (BTK) inhibitors, and digital biomarkers. Key events included the ACTRIMS Forum in West Palm Beach, the AAN Annual Meeting in San Diego, the CMSC Annual Meeting in Palm Springs, and the 41st ECTRIMS Congress in Helsinki.
Multiple sclerosis research and clinical care are fields characterized by rapid evolution. For neurologists, researchers, and patient advocates, the annual cycle of international and national conferences provides the essential framework for disseminating new data and refining treatment protocols. In 2025, the MS community focused heavily on the transition from managing inflammation to achieving neuroprotection and repair—a shift that continues to define clinical practice in 2026. This guide details the major 2025 conferences, their technical highlights, and how the information presented at these venues remains accessible for ongoing professional development.
The Significance of the 2025 MS Conference Circuit
The year 2025 was a landmark period for the MS community, as several long-term phase III clinical trials reached their primary endpoints, particularly in the realm of progressive MS (PMS). Conferences are not merely opportunities for networking; they are the "evidence gates" where peer-reviewed abstracts challenge existing paradigms.
In 2025, the overarching theme across all major meetings was Progression Independent of Relapse Activity (PIRA). Understanding that MS damage occurs even in the absence of clinical relapses has forced a re-evaluation of how we measure treatment success. The 2025 conferences provided the first large-scale data sets on how early intervention with high-efficacy disease-modifying therapies (DMTs) impacts long-term PIRA outcomes.
ACTRIMS Forum 2025 (West Palm Beach, FL)
The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) held its annual forum from February 27 to March 1, 2025. ACTRIMS is traditionally more research-heavy than clinical meetings, focusing on the "bench-to-bedside" pipeline.
The 2025 theme, "Progress and Paradigms," highlighted the latest in neuroimmunology. A significant portion of the forum was dedicated to the role of the innate immune system, specifically microglia and astrocytes, in driving chronic smoldering inflammation. Researchers presented findings on how these cells contribute to the "expanding lesion" phenomenon seen on 7-Tesla MRI, which has become a crucial biomarker for disease progression.
AAN Annual Meeting 2025 (San Diego, CA)
The American Academy of Neurology (AAN) Annual Meeting, held April 5–11, 2025, remains one of the largest gatherings of neurologists worldwide. While AAN covers all neurological disorders, its MS section is consistently one of the most robust.
In 2025, the MS highlights at AAN centered on health equity and access to care. Presentations addressed the disparities in MS diagnosis and treatment within Hispanic and Black communities, providing clinicians with actionable strategies to improve outreach and medication adherence. Additionally, several sessions focused on the pediatric-to-adult transition for young patients with MS, emphasizing the need for specialized multidisciplinary teams during this vulnerable period.
CMSC 2025: Bridging the Gap in Comprehensive Care
The Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting took place in Palm Springs, California, from May 28 to 31, 2025. Unlike ACTRIMS or ECTRIMS, CMSC is uniquely focused on the multidisciplinary care team, including nurses, physical therapists, social workers, and pharmacists.
Multidisciplinary Focus
The 2025 CMSC meeting emphasized "Whole-Person Health." This approach recognizes that while DMTs manage the biological progression of the disease, the symptoms of MS—such as fatigue, cognitive dysfunction, and bladder issues—require specialized rehabilitation and lifestyle interventions.
One of the most discussed topics was the implementation of lifestyle medicine in the clinical setting. This included evidence-based discussions on the "MS Diet," the role of high-intensity interval training (HIIT) in improving mobility, and the impact of mindfulness-based stress reduction (MBSR) on patient quality of life.
The Role of Rehabilitation Specialists
Rehabilitation professionals at CMSC 2025 presented new data on wearable technology for gait analysis. By using sensors to track "real-world" walking patterns outside of the clinic, therapists can now tailor exercise programs more effectively. This shift from episodic clinical assessment to continuous monitoring represents a major trend that has solidified in 2026.
ECTRIMS 2025: The Global Epicenter of MS Research
The 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) was held in Helsinki, Finland, from September 17 to 19, 2025. As the largest MS-specific conference in the world, ECTRIMS is where the most anticipated late-breaking clinical trials are typically revealed.
Key Research Pillars in Helsinki
- BTK Inhibitors: ECTRIMS 2025 was a definitive moment for Bruton’s tyrosine kinase (BTK) inhibitors. Following mixed results in earlier years, 2025 provided more clarity on which patient subsets benefit most from these small molecules that can cross the blood-brain barrier.
- Epstein-Barr Virus (EBV): Building on the groundbreaking discovery that EBV is a leading cause of MS, the 2025 congress featured several sessions on EBV-targeted therapies and vaccines. Discussions focused on whether clearing EBV-infected B-cells could halt disease progression.
- Artificial Intelligence in Radiology: The integration of AI into MRI analysis was a major technical highlight. In 2025, several software platforms demonstrated the ability to detect new lesions and brain volume loss with higher precision and speed than human radiologists alone, paving the way for more responsive treatment switches.
Patient Participation
ECTRIMS 2025 continued its tradition of including a "Patient Community Day." This session translated complex scientific findings into accessible language for patients and caregivers, ensuring that the people living with the disease are informed about the future of their care.
Comparison of Major 2025 MS Conferences
The following table summarizes the key logistical and thematic details of the primary MS conferences held in 2025.
| Conference | Date | Location | Primary Focus | Target Audience |
|---|---|---|---|---|
| ACTRIMS Forum | Feb 27 – Mar 1 | West Palm Beach, FL | Basic science & neuroimmunology | Researchers, Academics |
| AAN Annual Meeting | April 5 – 11 | San Diego, CA | General neurology & MS clinical updates | Neurologists, Residents |
| CMSC Annual Meeting | May 28 – 31 | Palm Springs, CA | Comprehensive & multidisciplinary care | Nurses, PTs, Social Workers |
| ECTRIMS Congress | Sept 17 – 19 | Helsinki, Finland | Global clinical trials & breakthrough research | Worldwide MS Specialists |
| LACTRIMS | Nov 2025 | Various (Regional) | MS in Latin American populations | Regional Clinicians |
Technical Depth: Breakthroughs in Biomarkers and Therapeutics
The 2025 conference season was characterized by a move toward precision medicine. This involves using specific biological markers to predict how an individual will respond to a specific therapy.
Neurofilament Light Chain (NfL) and GFAP
A recurring technical theme across 2025 meetings was the validation of blood-based biomarkers. Neurofilament Light Chain (NfL), a marker of axonal damage, and Glial Fibrillary Acidic Protein (GFAP), a marker of astrocytic activation, reached a level of evidence where they began to be integrated into clinical trial designs as secondary endpoints. Discussions in 2025 centered on establishing "normal" ranges for these markers across different age groups to make them useful in standard clinical practice.
Remyelination and Neuroprotection
While existing DMTs are excellent at preventing new inflammation, they do not repair existing damage. In 2025, ACTRIMS and ECTRIMS highlighted early-phase trials for agents designed to promote remyelination. These included monoclonal antibodies that block inhibitors of oligodendrocyte differentiation and small molecules that stimulate myelin repair. While these therapies are not yet standard of care in 2026, the 2025 data provided the foundation for the pivotal trials currently underway.
Accessing 2025 Conference Materials in 2026
For those who were unable to attend these events in person or virtually during 2025, the archives remain a vital resource for clinical evidence. Most major organizations provide access to their materials for at least 12 to 24 months following the event.
- Abstract Books: Usually available as a PDF or searchable database on the organization's website (e.g., ECTRIMS).
- On-Demand Sessions: Registered attendees of the 2025 meetings generally have continued access to video recordings. Non-attendees can often purchase access to "Best of" collections.
- CME Credits: Many 2025 conference recordings still offer Continuing Medical Education (CME) credits through the end of 2026, provided the post-test requirements are met.
- Published Supplements: High-impact journals often publish the "Late-Breaking Abstracts" from these conferences. Look for supplements in the Multiple Sclerosis Journal or Neurology.
Practical Considerations for Future Attendance
Reflecting on the 2025 cycle, several logistical trends emerged that are important for planning future conference attendance.
- Hybrid Models: Every major MS conference in 2025 offered a hybrid format. However, the "in-person" experience remains superior for networking and participating in hands-on workshops, such as MRI reading intensives.
- Early Bird Registration: The cost difference between early-bird and standard registration remains significant. For 2025, those who registered three to four months in advance saved approximately 30% on registration fees.
- Institutional Funding: Many hospitals and universities have specific deadlines for travel grant applications. Reviewing the 2025 schedules helped many clinicians secure 2026 funding by demonstrating the consistent value of these meetings.
Frequently Asked Questions
What was the most significant drug trial result presented in 2025? The most discussed results involved the Phase III trials for BTK inhibitors, specifically tolebrutinib and evobrutinib. While results were nuanced, they provided critical insights into managing non-relapsing progressive MS, which had previously lacked robust treatment options. These results have directly influenced the treatment algorithms we use in 2026.
Can I still earn CME credits from 2025 MS conferences? Yes, in many cases. Organizations like CMSC and AAN often keep their "Annual Meeting On-Demand" platforms active for up to a year. If you purchase access to these archives in 2026, you may still be eligible to earn credits, though you should check the specific expiration date for each session’s accreditation.
Where can I find the 2025 ECTRIMS abstracts? The 2025 ECTRIMS abstracts are hosted on the ECTRIMS Online Library. You can search by keyword, author, or session type. These abstracts are essential for citing the most recent data in research papers or clinical presentations.
Were there specific sessions for MS patients at the 2025 conferences? Yes, CMSC and ECTRIMS both featured dedicated patient programs. CMSC’s "Patient Education Day" and ECTRIMS’ "Patient Community Day" were designed to bridge the gap between high-level science and the practical needs of the MS community, focusing on topics like symptom management and insurance navigation.
How did 2025 conferences address "Smoldering MS"? "Smoldering MS" was a major buzzword in 2025. It refers to the slow, continuous progression of the disease that happens under the surface of stable MRI scans. Conferences focused on using new imaging techniques, such as Paramagnetic Rim Lesions (PRLs), to identify and treat this underlying activity earlier.
Recommendations for Moving Forward
To stay at the forefront of multiple sclerosis care, clinicians and researchers should treat the findings of 2025 as the current baseline for evidence-based medicine. If you have not yet reviewed the Helsinki Declaration or the updated PIRA consensus from ECTRIMS 2025, doing so is a priority for 2026.
Furthermore, begin planning for the 2026 and 2027 conference cycles early. Ensure your memberships in organizations like ACTRIMS or CMSC are current to benefit from discounted registration and exclusive access to abstract archives. For patients and advocates, following the "Plain Language Summaries" provided by these organizations is the best way to remain informed about the therapies that will likely become available in the next two to three years.
Medical Disclaimer: The information provided regarding 2025 multiple sclerosis conferences and medical research is for educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.
